Department of Systemic Rheumatic Diseases, V.A. Nasonova Research Institute of Rheumatology, Kashirskoe Shosse, 115522 Moscow, Russia.
Department of Organization and Economy of Pharmacy, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 8/2, Trubetskaya St., 119526 Moscow, Russia.
Int J Mol Sci. 2022 Aug 4;23(15):8656. doi: 10.3390/ijms23158656.
In addition to identifying the major B- and T-cell subpopulations involved in autoimmune rheumatic diseases (ARDs), in recent years special attention has been paid to studying the expression of their activation markers and immune checkpoints (ICPs). The activation markers on B and T cells are a consequence of the immune response, and these molecules are considered as sensitive specific markers of ARD activity and as promising targets for immunotherapy. ICPs regulate the activation of the immune response by preventing the initiation of autoimmune processes, and they modulate it by reducing immune cell-induced organ and tissue damage. The article considers the possible correlation of ICPs with the activity of ARDs, the efficacy of specific ARD treatments, and the prospects for the use of activation molecules and activation/blocking ICPs for the treatment of ARDs.
除了鉴定参与自身免疫性风湿性疾病（ARDs）的主要 B 细胞和 T 细胞亚群外，近年来，人们特别关注研究其激活标志物和免疫检查点（ICPs）的表达。B 细胞和 T 细胞上的激活标志物是免疫反应的结果，这些分子被认为是 ARD 活性的敏感特异性标志物，也是免疫治疗的有前途的靶点。本文考虑了 ICPs 与 ARD 活性、特定 ARD 治疗效果的可能相关性，以及使用激活分子和激活/阻断 ICPs 治疗 ARD 的前景。
